Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 5-year (y) follow-up results from CheckMate 649.

被引：0
|
作者：
Janjigian, Yelena Y.
Moehler, Markus H.
Ajani, Jaffer A.
Shen, Lin
Garrido, Marcelo
Gallardo, Carlos
Wyrwicz, Lucjan
Yamaguchi, Kensei
Cleary, James M.
Elimova, Elena
Bruges, Ricardo Elias
Karamouzis, Michalis
Skoczylas, Tomasz
Bragagnoli, Arinilda
Liu, Tianshu
Tehfe, Mustapha
McCraith, Stephen
Hu, Nan
Zhang, Jennifer
Shitara, Kohei
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Weill Cornell Med Coll, New York, NY USA
[3] Johannes Gutenberg Univ Mainz, D-55131 Mainz, Germany
[4] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[5] Peking Univ Canc Hosp & Inst, Beijing, Peoples R China
[6] Pontificia Univ Catolica, Santiago, Chile
[7] Fdn Arturo Lopez Perez, Providencia, Chile
[8] Narodowy Inst Onkol, Klin Onkol & Radioterapii, Warsaw, Poland
[9] Canc Inst Hosp JFCR, Tokyo, Japan
[10] Dana Farber Canc Inst, Boston, MA USA
[11] Princess Margaret Canc Ctr, Toronto, ON, Canada
[12] Inst Nacl Cancerol ESE, Bogota, Colombia
[13] Laiko Gen Hosp Athens, Athens, Greece
[14] Med Univ Lublin, Klin Chirurgii Ogolnej Gastroenterol & Nowotworow, Lublin, Poland
[15] Fundacao Pio XII, Barretos, Brazil
[16] Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China
[17] Ctr Hosp Univ Montreal, Montreal, PQ, Canada
[18] Bristol Myers Squibb, Princeton, NJ USA
[19] Natl Canc Ctr Hosp East, Kashiwa, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.4_suppl.398
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：398 / 398
页数：1
相关论文
共 50 条
  • [31] Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): 29-month (mo) follow-up from CheckMate 648.
    Kato, Ken
    Ajani, Jaffer A.
    Doki, Yuichiro
    Xu, Jianming
    Wyrwicz, Lucjan
    Motoyama, Satoru
    Ogata, Takashi
    Kawakami, Hisato
    Hsu, Chih-Hung
    Adenis, Antoine
    El Hajbi, Farid
    Di Bartolomeo, Maria
    Braghiroli, Maria Ignez Freitas Melro
    Holtved, Eva
    Murphy, Mariela A. Blum
    Patel, Apurva
    Hu, Nan
    Matsumura, Yasuhiro
    Chau, Ian
    Kitagawa, Yuko
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 290 - 290
  • [32] Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate 648 study.
    Chau, Ian
    Doki, Yuichiro
    Ajani, Jaffer A.
    Xu, Jianming
    Wyrwicz, Lucjan
    Motoyama, Satoru
    Ogata, Takashi
    Kawakami, Hisato
    Hsu, Chih-Hung
    Adenis, Antoine
    El Hajbi, Farid
    Di Bartolomeo, Maria
    Freitas Melro Braghiroli, Maria Ignez
    Holtved, Eva
    Xynos, Ioannis
    Liu, Xuan
    Lei, Ming
    Kondo, Kaoru
    Kato, Ken
    Kitagawa, Yuko
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (18)
  • [33] A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of patients in CheckMate 649: Nivolumab plus chemotherapy versus chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC)
    Sugarman, Ryan
    Botteman, Marc
    Rusibamayila, Nifasha
    Nguyen, Hiep
    Lin, Daniel
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [34] Health-related quality of life (HRQOL) in patients with advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma cancer (GC/GEJC/EAC): 36-month results of CheckMate 649 nivolumab plus chemotherapy (N plus C) versus chemo (C)
    Moehler, M.
    Wyrwicz, L.
    Chen, C.
    Davenport, E.
    Wang, J.
    Nathani, R.
    Kondo, K.
    Elimova, E.
    ANNALS OF ONCOLOGY, 2023, 34 : S185 - S185
  • [35] Nivolumab (NIVO) plus chemotherapy (chemo) or NIVO plus ipilimumab (IPI) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): first report of the CheckMate 648 study
    Greil, R.
    Chau, I
    Doki, Y.
    Ajani, J. A.
    Xu, J.
    Wyrwicz, L.
    Motoyama, S.
    Ogata, T.
    Kawakami, H.
    Hsu, C. -H
    Adenis, A.
    el Hajbi, F.
    Di Bartolomeo, M.
    Braghiroli, Ignez M.
    Holtved, E.
    Xynos, I
    Liu, X.
    Lei, M.
    Kondo, K.
    Kato, K.
    Kitagawa, Y.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 81 - 82
  • [36] Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): Additional analysies from 45-month (mo) follow-up of CheckMate 648
    Adenis, A.
    Chau, I.
    Ajani, J. A.
    Kitagawa, Y.
    Xu, J.
    Wyrwicz, L. S.
    Motoyama, S.
    Ogata, T.
    Kawakami, H.
    Hsu, C-H.
    El Hajbi, F.
    Di Bartolomeo, M.
    Braghiroli, M. I.
    Holtved, E.
    Murphy, M. Blum
    Zhang, J.
    Hu, N.
    Matsumura, Y.
    Kato, K.
    Doki, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S161 - S162
  • [37] Real-world (RW) effectiveness of nivolumab plus chemotherapy (NIVO plus chemo) in patients (pts) with advanced or metastatic gastric carcinoma, gastroesophageal junction carcinoma, or esophageal adenocarcinoma (GC/GEJC/EAC)
    Chau, Ian
    Barzi, Afsaneh
    Zhang, Ying
    You, Min
    Bertwistle, David
    Davis, Catherine
    Chen, Clara
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 295 - 295
  • [38] 5-year Survival Data in the First-line (1L) Treatment of advanced non-small cell Lung Cancer (mNSCLC) with Nivolumab (NIVO) plus Ipilimumab (IPI) vs Chemotherapy (chemo): Results of the CheckMate 227 Study
    Jaeschke, B.
    Brahmer, J. R.
    Lee, J. S.
    Ciuleanu, T. E.
    Caro, R. B.
    Nishio, M.
    Urban, L.
    Audigier-Valette, C.
    Lupinacci, L.
    Sangha, R.
    Paz-Ares, L. G.
    Reck, M.
    Borghaei, H.
    O'Byrne, K. J.
    Gupta, R. G.
    Bushong, J.
    Li, L.
    Blum, S. I.
    Eccles, L.
    Ramalingam, S. S.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 98 - 99
  • [39] Health-related quality of life (HRQOL) in patients with advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma cancer (GC/GEJC/EAC): 36-month results of CheckMate 649 nivolumab plus chemotherapy (N plus C) vs (C)
    Moehler, Markus
    Wyrwicz, Lucjan
    Chen, Clara
    Davenport, Eric
    Wang, Jinyi
    Nathani, Raheel
    Kondo, Kaoru
    Elimova, Elena
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 65 - 65
  • [40] First-line (1L) treatment patterns in advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma (GC/GEJC/EAC): Data from the Spanish AGAMENON-SEOM registry
    Jimenez-Fonseca, P.
    Carmona-Bayonas, A.
    Gallego Plazas, J.
    Custodio, A.
    Visa, L.
    Martinez de Castro, E.
    Gomez Gonzalez, L.
    Moreno Gutierrez, M.
    Polanco Sanchez, C.
    Xiao, H.
    ANNALS OF ONCOLOGY, 2022, 33 : S258 - S258
12345